Human Embryonic Stem Cells Market Synopsis:
Human Embryonic Stem Cells Market Size Was Valued at USD 3.02 Billion in 2023, and is Projected to Reach USD 7.81 Billion by 2032, Growing at a CAGR of 10.5 % From 2024-2032.
This particular market is defined as the global market with the research development and sales of stem cells that are developed from human embryos known as the Human Embryonic Stem Cells (hESC) Market. These are cells and unlike other specialized cells they can differentiate into any type of human cell, they are important for research and medical applications. It encompasses hESC lines used for research, products derived from hESCs for use in regenerative medicine, drug discovery, toxicology, and disease modeling, and culture media These hold great potential for personalized medicine, gene therapy, and cell based therapy; the market is comprised of biopharma companies, research institutions and hospitals, all working to deliver ‘next generation therapies in neurology, cardiology and oncology among other diseases. However, issues related to the ethical usage of human embryos still persists and also form some of the major factors affecting the market.
The Human Embryonic Stem Cells (hESC) Market is a relatively young market but one that is experiencing significant growth in recent years due to increase in knowledge about various aspects of stem cell biology, regenerative medicine and development of personalized therapies. This makes human embryonic stem cells especially valuable for research because these cells can become almost any cell of the human body, making them useful for studying disease, developing drugs and cell therapies. This has led to more funding being directed towards hESC based research especially in areas of gene therapy, tissues engineering and cells substitute. Some of the major uses include generation of models towards knowledge on diseases such as Alzheimers, Parkinsons and cancer besides the use of hESCs in evaluation of drug effect and safety. This according to the increase in chronic diseases and increased need for new therapies for diseases that currently have no cure.
As the market is a significant business, it is filled with ethical, regulatory and technical issues. Legal controversies surrounding embryonic research as well as regulatory measures still hold back growth as a major constraint. However, the need for human embryonic stem cells for drug discovery as well as in regenerative medicine and gene therapy continues to spur new technology and market developments. The increasing contribution of the biopharmaceutical companies, academic and research institution, and biotechnology firms in the stem cell research will help the market to grow in the future further. Besides, new scientific techniques such as CRISPR, as well as better approaches to grow and direct differentiation of hESCs, should help increase the applied potential of these cells and create a basis for more efficient and individualized treatments in the future years.
.webp)
Human Embryonic Stem Cells Market Trend Analysis:
Increasing Investment in the Stem Cell Research
- This report focuses on the Human Embryonic Stem Cells (hESC) market where new investment has started picking up mainly due to increased awareness about the importance of stem cell research across various therapeutic areas. Both public and private sectors have ramped up their commitments towards research based on stem cells realizing the possibilities it holds to meet the unmet need in medical field and the potentiality of changing drastically the way several chronic and genetic diseases are treated. This trend is most noticeable in the North America, Europe, and to extent Asia-Pacific where governments, biotechnology firms, and universities alike are gambling big bucks to know more about the reclamation capacities of human embryonic stem cells as a powerful biological resource.
- Stem cell funding has been important especially by governments, especially the US and China to finance the stem cell research. For example, a number of federal and state funding programs exists for stem cell research in the United States and, for example, the CIRM has invested billions of dollars in stem cell research since its founding. Further, there has been a notable engage of private capital and chief pharma firms to fund hESC for therapeutic intent including regenerative medicine, tissue engineering, and gene therapy. The following investments have helped facilitate the creation of new hESC-derived therapies to manage neurological diseases such as Parkinson and Alzheimer, cardiovascular diseases and some types of cancer.
A Key to Revolutionizing Drug Discovery and Disease Modeling
- hESC represent a revolutionary resource in drug development with potential to radically enhance R&D into novel drugs for disease treatment. This way, hESCs provide a model of specific diseases, so the corresponding reactions can be better forecasted in live conditions, with eventual medical productions. This innovation allows companies dealing in therapeutic products to filter compounds quicker and find phone drug leads and monitor the toxicity and efficacy of new therapies at the initial stage.
- Therefore, based on features such as genetic heterogeneity and developmental plasticity, hESCs can provide insights into disease modeling when the conditions under study are Alzheimer’s disease, Parkinson’s disease, cancer, and heart disease. They can be converted to numerous cell forms, and as a result, disease processes can be analyzed on a cellular level. Therefore, the use of hESCs as a disease model offers unique view on the disease course, potential treatments and genetic predispositions. Maeuro wants to be an essential participant in the development of new human-specific disease models to contribute the best possible solutions to the concept of precision medicine and drug safety and efficacy. Hence there is expected improvement in the stem cell technologies and better comprehendible regulatory measures, hESCs are expected to have a better and central position in future in the drug discovery process and in the development of the novel therapeutic resources.
Human Embryonic Stem Cells Market Segment Analysis:
Human Embryonic Stem Cells Market is Segmented on the basis of Type, Application, End User, and Region
By Type, Human Embryonic Stem Cell Lines segment is expected to dominate the market during the forecast period
- The Human Embryonic Stem Cell Lines segment is expected to lead the market over the forecast period due to being the kind of stem cells that an numerous research and therapeutic uses.. These stem cel ls are taken directly from human embryos by removing the early-stage human embryos and are pluripotent; this gives them the potential of developing into different cell types and are very useful in cloning diseases, in toxicity testing and tissue regeneration. These stem cell lines are reliably sustainable as pluripotent cells that may be grown and manipulated for the clinical and research uses. Presumably because they are essential for the progression of cell based therapies and personalized medicine, the global demand for hESC lines is expected to remain high.• Moreover, these stem cell lines are crucial to biopharmaceutical and biotechnology applications and include accurate disease models and drugs’ testing.tions. Human embryonic stem cell lines are derived from early-stage human embryos and possess the ability to differentiate into various cell types, making them invaluable in disease modeling, drug discovery, and regenerative medicine. These stem cell lines provide a consistent and reproducible source of pluripotent cells that can be cultured and manipulated for various clinical and research applications. As they are critical for advancing the development of cell-based therapies and personalized medicine, the demand for human embryonic stem cell lines is anticipated to remain strong.
- Furthermore, these stem cell lines play a central role in biopharmaceutical and biotechnology research, enabling the development of advanced disease models and drug testing platforms. Human embryonic stem cell lines also possess the potential for use in regenerative medicine where these cells are being used to produce tissue and organ scaffolding for a definitive treatment of degenerative diseases, trauma and congenital abnormalities. The growth of stem cells research and the new clinical applications discovered over a period will lead to human embryonic stem cells to remain the market leader across the forecast period.
By Application, Regenerative Medicine segment expected to held the largest share
- The Regenerative Medicine is also likely to dominate the Human Embryonic Stem Cells (hESCs) market in the forecast period. Stem cell research is among the most exciting fields in biotechnology, and hESCs play key role in the process of renewing tissues and organs for repair. Being able to generate any specialized cell for the developing organism or adult organism, human embryonic stem cells hold great promise as a means to create therapies for chronic diseases, injuries, and degenerative diseases, such as cardiovascular disease, neurological disorders, diabetes, and musculoskeletal diseases.
- The increasing need for therapeutic solutions in contemporary societies where conventional treatments are scarce or lacking in treatment for spinal cord injuries and neural disorders, including Alzheimer’s and Parkinson’s disease, has introduced considerable interest and investment in regenerative sciences. Besides this, the hESC-derived cells have the major advantage of likely elimination of organ shortage for transplantation by means of providing tissue-specific cells or even the entire organs. This is especially so since the regenerative medicine sector, will lead the market by growing and transforming the healthcare environment as it provides solution for diseases and conditions that are hard to treat or cure. This requirement coupled with the continuous new knowledge and innovations in clinical medicine make regenerative medicine as the leading application of human embryonic stem cells in the market.
Human Embryonic Stem Cells Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America will lead the Human Embryonic Stem Cells Market during the projected period because of the well-developed research environment, adequate funding, and well-developed healthcare facilities. In particular, the United States stands out among the countries, many universities, research centers and biotech companies carry out involving research on stem cells and work on the possible methods of using human embryonic stem cells. This funding and support has not only increased from government but also provenances like National Institutes of Health (NIH) providing funds related stem cell and clinical trial.
- Besides research sponsorship, advanced development comes into view by having biopharmaceutical and biotechnology industries all over North America, where number of genuine corporations, participating in/personalizing stem cell based products for treatment involving regenerative medicine and medicines formulation, also the cell based therapies. Leading healthcare facilities and an increasing trend of people seeking better treatment compel the regional advancement of human embryonic stem cells. North Americas position is also boosted by appropriate polices and legislation that provide support and facilitate development as well as commercialization of stem cell technology. These factors make North America a dominant market in the global human embryonic stem cell market while retaining its dominance in the forecast period.
Active Key Players in the Human Embryonic Stem Cells Market
- Advanced Cell Technology, Inc. (United States)
- Asterand Bioscience (United Kingdom)
- Biocon Ltd. (India)
- Cellartis AB (Sweden)
- Charles River Laboratories International, Inc. (United States)
- Cytiva (formerly GE Healthcare Life Sciences) (United States)
- Fujifilm Irvine Scientific (United States)
- KURABO Industries Ltd. (Japan)
- Lonza Group AG (Switzerland)
- MilliporeSigma (Merck KGaA) (Germany)
- Novartis AG (Switzerland)
- PromoCell GmbH (Germany)
- ReproCELL Inc. (Japan)
- Roche Holding AG (Switzerland)
- Sigma-Aldrich Corporation (United States)
- Stemcell Technologies Inc. (Canada)
- Stemina Biomarker Discovery, Inc. (United States)
- Thermo Fisher Scientific Inc. (United States)
- Other Active Players
|
Human Embryonic Stem Cells Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.02 Billion |
|
Forecast Period 2024-32 CAGR: |
10.5 % |
Market Size in 2032: |
USD 7.81 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Human Embryonic Stem Cells Market by Type
4.1 Human Embryonic Stem Cells Market Snapshot and Growth Engine
4.2 Human Embryonic Stem Cells Market Overview
4.3 Human Embryonic Stem Cell Lines
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Human Embryonic Stem Cell Lines: Geographic Segmentation Analysis
4.4 Human Embryonic Stem Cell-Derived Products
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Human Embryonic Stem Cell-Derived Products: Geographic Segmentation Analysis
4.5 Stem Cell Culture Media
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Stem Cell Culture Media: Geographic Segmentation Analysis
Chapter 5: Human Embryonic Stem Cells Market by Application
5.1 Human Embryonic Stem Cells Market Snapshot and Growth Engine
5.2 Human Embryonic Stem Cells Market Overview
5.3 Regenerative Medicine
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Regenerative Medicine: Geographic Segmentation Analysis
5.4 Drug Discovery and Toxicology Testing
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Drug Discovery and Toxicology Testing: Geographic Segmentation Analysis
5.5 Disease Modeling
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Disease Modeling: Geographic Segmentation Analysis
5.6 Cell-based Therapies
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Cell-based Therapies: Geographic Segmentation Analysis
5.7 Gene Therapy Research
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Gene Therapy Research: Geographic Segmentation Analysis
Chapter 6: Human Embryonic Stem Cells Market by End User
6.1 Human Embryonic Stem Cells Market Snapshot and Growth Engine
6.2 Human Embryonic Stem Cells Market Overview
6.3 Biopharmaceutical Companies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Biopharmaceutical Companies: Geographic Segmentation Analysis
6.4 Academic and Research Institutions
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Academic and Research Institutions: Geographic Segmentation Analysis
6.5 Contract Research Organizations (CROs)
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Contract Research Organizations (CROs): Geographic Segmentation Analysis
6.6 Hospitals and Healthcare Providers
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Hospitals and Healthcare Providers: Geographic Segmentation Analysis
6.7 Biotechnology Companies
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Biotechnology Companies: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Human Embryonic Stem Cells Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ADVANCED CELL TECHNOLOGY INC. (UNITED STATES)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ASTERAND BIOSCIENCE (UNITED KINGDOM)
7.4 BIOCON LTD. (INDIA)
7.5 CELLARTIS AB (SWEDEN)
7.6 CHARLES RIVER LABORATORIES INTERNATIONAL INC. (UNITED STATES)
7.7 CYTIVA (FORMERLY GE HEALTHCARE LIFE SCIENCES) (UNITED STATES)
7.8 FUJIFILM IRVINE SCIENTIFIC (UNITED STATES)
7.9 KURABO INDUSTRIES LTD. (JAPAN)
7.10 LONZA GROUP AG (SWITZERLAND)
7.11 MILLIPORESIGMA (MERCK KGAA) (GERMANY)
7.12 NOVARTIS AG (SWITZERLAND)
7.13 PROMOCELL GMBH (GERMANY)
7.14 REPROCELL INC. (JAPAN)
7.15 ROCHE HOLDING AG (SWITZERLAND)
7.16 SIGMA-ALDRICH CORPORATION (UNITED STATES)
7.17 STEMCELL TECHNOLOGIES INC. (CANADA)
7.18 STEMINA BIOMARKER DISCOVERY INC. (UNITED STATES)
7.19 THERMO FISHER SCIENTIFIC INC. (UNITED STATES)
7.20 OTHER ACTIVE PLAYERS
Chapter 8: Global Human Embryonic Stem Cells Market By Region
8.1 Overview
8.2. North America Human Embryonic Stem Cells Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Type
8.2.4.1 Human Embryonic Stem Cell Lines
8.2.4.2 Human Embryonic Stem Cell-Derived Products
8.2.4.3 Stem Cell Culture Media
8.2.5 Historic and Forecasted Market Size By Application
8.2.5.1 Regenerative Medicine
8.2.5.2 Drug Discovery and Toxicology Testing
8.2.5.3 Disease Modeling
8.2.5.4 Cell-based Therapies
8.2.5.5 Gene Therapy Research
8.2.6 Historic and Forecasted Market Size By End User
8.2.6.1 Biopharmaceutical Companies
8.2.6.2 Academic and Research Institutions
8.2.6.3 Contract Research Organizations (CROs)
8.2.6.4 Hospitals and Healthcare Providers
8.2.6.5 Biotechnology Companies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Human Embryonic Stem Cells Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Type
8.3.4.1 Human Embryonic Stem Cell Lines
8.3.4.2 Human Embryonic Stem Cell-Derived Products
8.3.4.3 Stem Cell Culture Media
8.3.5 Historic and Forecasted Market Size By Application
8.3.5.1 Regenerative Medicine
8.3.5.2 Drug Discovery and Toxicology Testing
8.3.5.3 Disease Modeling
8.3.5.4 Cell-based Therapies
8.3.5.5 Gene Therapy Research
8.3.6 Historic and Forecasted Market Size By End User
8.3.6.1 Biopharmaceutical Companies
8.3.6.2 Academic and Research Institutions
8.3.6.3 Contract Research Organizations (CROs)
8.3.6.4 Hospitals and Healthcare Providers
8.3.6.5 Biotechnology Companies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Human Embryonic Stem Cells Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Type
8.4.4.1 Human Embryonic Stem Cell Lines
8.4.4.2 Human Embryonic Stem Cell-Derived Products
8.4.4.3 Stem Cell Culture Media
8.4.5 Historic and Forecasted Market Size By Application
8.4.5.1 Regenerative Medicine
8.4.5.2 Drug Discovery and Toxicology Testing
8.4.5.3 Disease Modeling
8.4.5.4 Cell-based Therapies
8.4.5.5 Gene Therapy Research
8.4.6 Historic and Forecasted Market Size By End User
8.4.6.1 Biopharmaceutical Companies
8.4.6.2 Academic and Research Institutions
8.4.6.3 Contract Research Organizations (CROs)
8.4.6.4 Hospitals and Healthcare Providers
8.4.6.5 Biotechnology Companies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Human Embryonic Stem Cells Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Type
8.5.4.1 Human Embryonic Stem Cell Lines
8.5.4.2 Human Embryonic Stem Cell-Derived Products
8.5.4.3 Stem Cell Culture Media
8.5.5 Historic and Forecasted Market Size By Application
8.5.5.1 Regenerative Medicine
8.5.5.2 Drug Discovery and Toxicology Testing
8.5.5.3 Disease Modeling
8.5.5.4 Cell-based Therapies
8.5.5.5 Gene Therapy Research
8.5.6 Historic and Forecasted Market Size By End User
8.5.6.1 Biopharmaceutical Companies
8.5.6.2 Academic and Research Institutions
8.5.6.3 Contract Research Organizations (CROs)
8.5.6.4 Hospitals and Healthcare Providers
8.5.6.5 Biotechnology Companies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Human Embryonic Stem Cells Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Type
8.6.4.1 Human Embryonic Stem Cell Lines
8.6.4.2 Human Embryonic Stem Cell-Derived Products
8.6.4.3 Stem Cell Culture Media
8.6.5 Historic and Forecasted Market Size By Application
8.6.5.1 Regenerative Medicine
8.6.5.2 Drug Discovery and Toxicology Testing
8.6.5.3 Disease Modeling
8.6.5.4 Cell-based Therapies
8.6.5.5 Gene Therapy Research
8.6.6 Historic and Forecasted Market Size By End User
8.6.6.1 Biopharmaceutical Companies
8.6.6.2 Academic and Research Institutions
8.6.6.3 Contract Research Organizations (CROs)
8.6.6.4 Hospitals and Healthcare Providers
8.6.6.5 Biotechnology Companies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Human Embryonic Stem Cells Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Type
8.7.4.1 Human Embryonic Stem Cell Lines
8.7.4.2 Human Embryonic Stem Cell-Derived Products
8.7.4.3 Stem Cell Culture Media
8.7.5 Historic and Forecasted Market Size By Application
8.7.5.1 Regenerative Medicine
8.7.5.2 Drug Discovery and Toxicology Testing
8.7.5.3 Disease Modeling
8.7.5.4 Cell-based Therapies
8.7.5.5 Gene Therapy Research
8.7.6 Historic and Forecasted Market Size By End User
8.7.6.1 Biopharmaceutical Companies
8.7.6.2 Academic and Research Institutions
8.7.6.3 Contract Research Organizations (CROs)
8.7.6.4 Hospitals and Healthcare Providers
8.7.6.5 Biotechnology Companies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Human Embryonic Stem Cells Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.02 Billion |
|
Forecast Period 2024-32 CAGR: |
10.5 % |
Market Size in 2032: |
USD 7.81 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
